References

[1] . 2000;342:1334-1349.
[2] Fanelli et al. Acute respiratory distress syndrome: new definition, current and future therapeutic options. J Thorac Dis 2013;5(3):326-334.
[3] Swaroopa et al. Association of serum interleukin-6, interleukin-8, and Acute Physiology and Chronic Health Evaluation II score with clinical outcome in patients with acute respiratory distress syndrome. Indian J Crit Care Med. 2016; 20(9):518-525.
[4] Didion SP. Cellular and oxidative mechanisms associated with interleukin-6 signaling in the vasculature. Int J Mol Sci. 2017; 18, 2563.
[5] Park WY, Goodman RB, Steinberg KP. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;164:1896–1903.
[6] Meduri GU, Headley S, Kohler G, et al. Peristent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest. 1995;107:1062–1073.
[7] Ding C, Jones G. Technology evaluation: MRA, Chugai. Current Opinion in Molecular Therapeutics. 2003; 5(1):64-69.
[8] Ito H. IL-6 and Crohn’s Disease. Curr Drug Targets Inflamm Allergy. 2003; 2(2):125-30.
[9] Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T cell therapy–assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47.
[10] Khadka, Sakemura, Kenderian, Johnson. Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy. 2019;11(10):851-857.
[11] Cross LJM, Matthay MA. Biomarkers in acute lung injury: insights into pathogenesis of acute lung injury. Crit Care Clin. 2011 April;27(2):355–377.
[12] Parsons PE, Eisner MD, Thompson BT, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med. 2005;33:1–6.
[13] Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The Pro- And Anti-Inflammatory Properties of the Cytokine interleukin-6. Biochim Piophys Acta. 2011; 1813(5): 878-88.
[14] Chalaris A, Rabe B, Paliga K, et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the pro-inflammatory trans-signaling function of neutrophils. Blood. 2007;110:1748–1755.
[15] Rabe B, Chalaris A, May U, et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood. 2008;111:1021–1028.
[16] Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004;21:491–501.
[17] Chen Q, Fisher DT, Clancy KA, et al. Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol. 2006;7:1299–1308.
[18] Oberg HH, Wesch D, Grussel S, Rose-John S, Kabelitz D. Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25- and CD25 high regulatory T cells. Int Immunol. 2006;18:555–563.
[19] Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches., Expert Opin Ther Targets. 2007;11;613–624.
[20] Scheller J, Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol. 2006;195:173–183.
[21] Jostock T, Müllberg J, Özbek S, et al. Soluble gp130 is the natural inhibitor of soluble IL-6R transsignaling responses. Eur J Biochem. 2001;268:160–167.
[22] Rose-John. IL-6 trans-signaling via the Soluble il-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237-1247.
[23] Sylvant Highlights of Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf
[24] . Int. J. Cancer. 2004; 111: 592-595.
[25] Le RQ et al., FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. The Oncologist 2018; 23:943-947.
[26] Gibiansky and Frey. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach. J Pharmacokinet Pharmacodyn. 2012; 39:5-16.
[27] Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. The AAPS Journal. 2010; 12(1): 33-43.
[28] Channappanavar and Perlman. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017; 39:529-539.
[29] Peiris JS et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361(9371):1767–1772.
[30] Al-Tawfiq JA, et al. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis. 2014;59(2):160–165.
[31] Arabi YM, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160:389–397.
[32] Gu J, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415–424.
[33] Ng DL, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol. 2016;186(3):652–658.
[34] Falzarano D, et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313–1317.
[35] Omrani AS, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090–1095.
[36] WHO R&D Blueprint: Covid 19: Informal consultation on the potential role of IL-6/IL-1 antagonists in the clinical management of COVID 19 infection.
[37] Regeneron and Sanofi Provide Update on US Phase 2/3 Adaptive-Designed Trial of Kevzara® (Sarilumab) in Hospitalized COVID-19 Patients. News Release. Regeneron; April 27, 2020. Accessed April 27, 2020. https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive.
[38] van Zaanen HC, Koopmans RP, Aarden LA, Rensink HJ, Stouthard JM, Warnaar SO, Lokhorst HM, van Oers MH.J Clin Invest. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.1996 Sep 15;98(6):1441-8.
[39] Deisseroth A, Ko CW, Nie L, Zirkelbach JF, Zhao L, Bullock J, Mehrotra N, Del Valle P, Saber H, Sheth C, Gehrke B, Justice R, Farrell A, Pazdur R. FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease. Clin Cancer Res. 2015 Mar 1;21(5):950-4.
[40] Wang, W., Wang, X., Doddareddy, R. et al. Mechanistic Pharmacokinetic/Target Engagement/Pharmacodynamic (PK/TE/PD) Modeling in Deciphering Interplay Between a Monoclonal Antibody and Its Soluble Target in Cynomolgus Monkeys. AAPS J 2014; 16, 129–139.
[41] Mihara M, Kasutani K, Okazaki M, Nakamura A, Sawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. International Immunopharmacology 2005; 5(12): 1731-1740.